Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;10(6):e404-e411.
doi: 10.1016/S2352-3018(23)00079-6. Epub 2023 May 10.

The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities

Affiliations
Review

The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities

Jessica E Haberer et al. Lancet HIV. 2023 Jun.

Abstract

The effectiveness of HIV pre-exposure prophylaxis (PrEP) hinges on adherence, which has been restricted by multifaceted barriers. Uptake of PrEP has been impeded by poor access resulting from high costs, provider uncertainty, discrimination, stigma, and poor understanding within the health-care community and the public of who can benefit from PrEP. Other important barriers to adherence and persistence over time relate to individuals (eg, depression) and their community, partners, and family (eg, poor support), and their effects vary substantially with each person, population, and setting. Despite these challenges, key opportunities for improving PrEP adherence exist, including novel delivery systems, tailored individual interventions, mobile health and digital health interventions, and long-acting formulations. Objective monitoring strategies will help to improve adherence interventions and alignment of PrEP use with the need for HIV prevention (ie, prevention-effective adherence). The future of PrEP adherence lies in person-centred approaches to service delivery that meet the needs of individuals while creating supportive environments and facilitating health-care access and delivery.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests JEH reports consulting fees from Merck and owns stock in Natera. AM has received grants from Gilead Sciences, consulting fees from Viiv, and honoraria from Cepheid. KHM has received grants from and participated on scientific advisory boards for Gilead Sciences and Merck.

Substances

LinkOut - more resources